Canada Markets open in 6 hrs 48 mins

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.55-0.46 (-1.59%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close29.01
Open29.23
Bid0.00 x 1100
Ask0.00 x 800
Day's Range28.48 - 29.30
52 Week Range27.66 - 54.85
Volume91,260
Avg. Volume221,375
Market Cap1.331B
Beta (5Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateAug. 05, 2021 - Aug. 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.22
  • GlobeNewswire

    Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

    WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021. Details of Replimune’s poster presentations: Abstract Title: A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-

  • Simply Wall St.

    We're Not Worried About Replimune Group's (NASDAQ:REPL) Cash Burn

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

    Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022 Initial data with RP2 as monotherapy and in combination with Opdivo® (nivolumab) in patients with difficult-to-treat and anti-PD-1 failed cancers supports expanding the Phase 1 clinical trial to focus on patients whose tumors have metastasized